MASS Stock Overview
A commercial-stage technology company, provides various purpose-built handheld and desktop mass spectrometry devices to interrogate unknown and invisible materials in life sciences research, bioprocessing, pharma/biopharma, forensics, and adjacent markets.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
908 Devices Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$3.50 |
| 52 Week High | US$12.51 |
| 52 Week Low | US$3.36 |
| Beta | 0.97 |
| 11 Month Change | -1.96% |
| 3 Month Change | -28.28% |
| 1 Year Change | -41.37% |
| 33 Year Change | -89.16% |
| 5 Year Change | n/a |
| Change since IPO | -92.86% |
Recent News & Updates
908 Devices: Key Investor Now Selling
Sep 08Why We're Not Concerned Yet About 908 Devices Inc.'s (NASDAQ:MASS) 29% Share Price Plunge
Aug 16
Recent updates
908 Devices: Key Investor Now Selling
Sep 08Why We're Not Concerned Yet About 908 Devices Inc.'s (NASDAQ:MASS) 29% Share Price Plunge
Aug 16We Think 908 Devices (NASDAQ:MASS) Can Afford To Drive Business Growth
Mar 30Investors Appear Satisfied With 908 Devices Inc.'s (NASDAQ:MASS) Prospects
Dec 18908 Devices Q2 2022 Earnings Preview
Aug 08908 Devices Aims For Broadened Footprint
Feb 02Shareholder Returns
| MASS | US Electronic | US Market | |
|---|---|---|---|
| 7D | -3.6% | -1.3% | 0.4% |
| 1Y | -41.4% | 26.8% | 32.6% |
Return vs Industry: MASS underperformed the US Electronic industry which returned 26.8% over the past year.
Return vs Market: MASS underperformed the US Market which returned 32.6% over the past year.
Price Volatility
| MASS volatility | |
|---|---|
| MASS Average Weekly Movement | 9.0% |
| Electronic Industry Average Movement | 7.0% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in US Market | 15.0% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: MASS has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: MASS's weekly volatility (9%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2012 | 230 | Kevin Knopp | 908devices.com |
908 Devices Inc., a commercial-stage technology company, provides various purpose-built handheld and desktop mass spectrometry devices to interrogate unknown and invisible materials in life sciences research, bioprocessing, pharma/biopharma, forensics, and adjacent markets. The company’s products include MX908, a handheld, battery-powered, and Mass Spec device that is designed for rapid analysis of solid, liquid, vapor, and aerosol materials of unknown identity; Rebel, a small desktop analyzer that provides real-time information on the extracellular environment in bioprocesses; and Maverick, an optical in-line analyzer that offers real-time monitoring and control of multiple bioprocess parameters, including glucose, lactate, and total biomass in mammalian cell cultures, as well as provides process fingerprint data to support large-scale efforts in predictive bioprocess modeling. Its products also comprise Maven and Trace C2, an online device for bioprocess monitoring and control; and ZipChip solution, a plug-and-play, high-resolution separation platform that optimizes Mass Spec sample analysis.
908 Devices Inc. Fundamentals Summary
| MASS fundamental statistics | |
|---|---|
| Market cap | US$121.30m |
| Earnings (TTM) | -US$37.98m |
| Revenue (TTM) | US$52.69m |
2.3x
P/S Ratio-3.2x
P/E RatioIs MASS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| MASS income statement (TTM) | |
|---|---|
| Revenue | US$52.69m |
| Cost of Revenue | US$25.12m |
| Gross Profit | US$27.57m |
| Other Expenses | US$65.55m |
| Earnings | -US$37.98m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.10 |
| Gross Margin | 52.32% |
| Net Profit Margin | -72.10% |
| Debt/Equity Ratio | 0% |
How did MASS perform over the long term?
See historical performance and comparison